Russia's R-Pharm plans to produce Sputnik V vaccine for EU market

16 November 2021

The Russian drugmaker R-Pharm plans to produce Sputnik V vaccine in the European Union and has received a three-year loan of 50 million ($57 million) to expand the company's production in Illertissen, Germany.

This site was acquired by R-Pharm in 2014 from Pfizer (NYSE: PFE). R-Pharm says that total production will amount up to 150 million doses per year. In addition, the site will be used for the production of drug for the treatment of COVID-19-artelegia. Sputnik V for the German market (after its approval by the European Medicines Agency) will be also produced at the Illertissen site.

The company does not specify which vaccines it intend to produce in Germany before receiving permission for Sputnik V. However, according to the Russian Kommersant business paper, citing its sources, that could be Vaxzevria vaccine from AstraZeneca (LSE: AZN).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK